X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (182603) 182603
Newspaper Article (10386) 10386
Newsletter (6036) 6036
Magazine Article (1389) 1389
Book Chapter (415) 415
Book / eBook (281) 281
Web Resource (125) 125
Trade Publication Article (87) 87
Transcript (63) 63
Book Review (55) 55
Conference Proceeding (52) 52
Dissertation (43) 43
Reference (33) 33
Publication (30) 30
Report (9) 9
Streaming Video (7) 7
Journal / eJournal (6) 6
Government Document (4) 4
Paper (3) 3
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (147359) 147359
anti-bacterial agents - therapeutic use (71803) 71803
female (70315) 70315
male (70152) 70152
adult (44166) 44166
middle aged (42141) 42141
infectious diseases (35261) 35261
antibiotics (33634) 33634
microbiology (33053) 33053
aged (32284) 32284
animals (29652) 29652
anti-bacterial agents - pharmacology (28661) 28661
bacterial infections (28339) 28339
infections (28253) 28253
microbial sensitivity tests (24047) 24047
bacterial infections - drug therapy (21609) 21609
anti-bacterial agents - administration & dosage (21212) 21212
health aspects (21038) 21038
adolescent (20781) 20781
treatment outcome (20394) 20394
pharmacology & pharmacy (20248) 20248
bacteria (20105) 20105
child (19914) 19914
infection (19064) 19064
research (18430) 18430
pneumonia (15816) 15816
risk factors (15750) 15750
child, preschool (14631) 14631
drug resistance (14370) 14370
immunology (14055) 14055
retrospective studies (13725) 13725
infant (12893) 12893
drug therapy (12707) 12707
care and treatment (12263) 12263
drug resistance, bacterial (12038) 12038
aged, 80 and over (12027) 12027
analysis (11521) 11521
medicine, general & internal (11176) 11176
bacterial pneumonia (11074) 11074
drug therapy, combination (10860) 10860
mortality (10743) 10743
diagnosis (10715) 10715
research article (10681) 10681
medicine (10337) 10337
staphylococcal infections - drug therapy (10282) 10282
drug resistance in microorganisms (10268) 10268
epidemiology (9849) 9849
therapy (9579) 9579
mice (9414) 9414
pediatrics (9194) 9194
prospective studies (9018) 9018
young adult (8868) 8868
medical research (8826) 8826
children (8647) 8647
surgery (8590) 8590
anti-bacterial agents - adverse effects (8395) 8395
resistance (8395) 8395
drug resistance, microbial (8090) 8090
antimicrobial agents (8075) 8075
prevalence (7967) 7967
infant, newborn (7760) 7760
time factors (7690) 7690
management (7647) 7647
hospitals (7619) 7619
pathogens (7302) 7302
patients (7273) 7273
bacterial infections and mycoses (6958) 6958
disease (6920) 6920
medicine, experimental (6890) 6890
internal medicine (6599) 6599
bacterial infections - microbiology (6345) 6345
drug resistance, multiple, bacterial (6334) 6334
staphylococcus aureus (6311) 6311
tuberculosis (6288) 6288
bacteria - drug effects (6231) 6231
antimicrobial resistance (6051) 6051
multidisciplinary sciences (6045) 6045
antibacterial agents (5991) 5991
medicine & public health (5976) 5976
escherichia-coli (5943) 5943
bacteremia (5904) 5904
staphylococcus aureus - drug effects (5769) 5769
studies (5661) 5661
staphylococcal infections - microbiology (5614) 5614
sepsis (5585) 5585
risk-factors (5497) 5497
urinary tract infections - drug therapy (5429) 5429
infectious disease (5428) 5428
follow-up studies (5391) 5391
prevention (5319) 5319
usage (5267) 5267
helicobacter infections - drug therapy (5249) 5249
acute disease (5228) 5228
gastroenterology & hepatology (5212) 5212
nosocomial infections (5133) 5133
cross infection - drug therapy (5127) 5127
abridged index medicus (5115) 5115
anti-bacterial agents (5106) 5106
science (5043) 5043
respiratory tract infections - drug therapy (5041) 5041
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (131) 131
Online Resources - Online (53) 53
Collection Dvlpm't (Acquisitions) - Vendor file (19) 19
UofT at Mississauga - Stacks (17) 17
UofT at Scarborough - Stacks (7) 7
Collection Dvlpm't (Acquisitions) - Closed Orders (6) 6
St. Michael's Hospital - Stacks (6) 6
Gerstein Science - Periodical Stacks (4) 4
Scarborough Hospital - Birchmount (4) 4
Scarborough Hospital - Online (4) 4
Lakeridge Health Sciences - Oshawa (3) 3
Scarborough Hospital - General (3) 3
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (3) 3
UTL at Downsview - May be requested (3) 3
Credit Valley Hospital - Stacks (2) 2
Engineering & Comp. Sci. - Stacks (2) 2
Gerstein Science - Bindery (2) 2
Sunnybrook Health Sciences Centre - Sunnybrook Reference (2) 2
West Park Healthcare Centre - Stacks (2) 2
Women's College Hospital - Stacks (2) 2
Baycrest Hospital - Stacks (1) 1
Chemistry (A D Allen) - Stacks (1) 1
Credit Valley Hospital - Reserve desk (1) 1
Dentistry (Harry R Abbott) - May be requested in 6-10 wks (1) 1
Dentistry (Harry R Abbott) - Withdrawn (1) 1
Earth Sciences (Noranda) - Stacks (1) 1
Gerstein Science - Circulation Desk (1) 1
Law (Bora Laskin) - Stacks (1) 1
Providence Healthcare - Stacks (1) 1
Sunnybrook Health Sciences Centre - Online (1) 1
Thomas Fisher Rare Book - Rare Book (1) 1
Trillium Health Centre - Reserve desk (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (182698) 182698
French (4017) 4017
German (3610) 3610
Japanese (3470) 3470
Spanish (2570) 2570
Russian (2361) 2361
Italian (1187) 1187
Polish (661) 661
Chinese (606) 606
Dutch (420) 420
Danish (334) 334
Turkish (250) 250
Romanian (232) 232
Portuguese (231) 231
Czech (215) 215
Swedish (205) 205
Norwegian (189) 189
Hungarian (175) 175
Bulgarian (132) 132
Hebrew (117) 117
Korean (105) 105
Finnish (102) 102
Croatian (87) 87
Ukrainian (80) 80
Serbian (64) 64
Slovak (36) 36
Lithuanian (16) 16
Icelandic (10) 10
Arabic (9) 9
Slovenian (9) 9
Afrikaans (5) 5
Bosnian (3) 3
Greek (2) 2
Hindi (2) 2
Urdu (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Burns, ISSN 0305-4179, 2017, Volume 43, Issue 3, pp. 642 - 653
Highlights • Burn depth/agent increases risk of developing an infection. • Infections found folliculitis, burn wound, urinary tract, pneumonia, CVC and bloodstream... 
Critical Care | Nosocomial infection | Burn wound infection | Pneumonia | Urinary tract infection | Health care related infection | Burns | URINARY-TRACT-INFECTION | MORTALITY | SURGERY | RISK-FACTORS | DERMATOLOGY | REPLACEMENT | BACTERIOLOGY | CATHETERS | INTENSIVE-CARE-UNIT | SURVEILLANCE | ASSOCIATION | BLOOD-STREAM INFECTIONS | CRITICAL CARE MEDICINE | Escherichia coli | Humans | Middle Aged | Child, Preschool | Male | Young Adult | Folliculitis - epidemiology | Aged, 80 and over | Urinary Tract Infections - microbiology | Catheter-Related Infections - epidemiology | Child | Infant, Newborn | Staphylococcus aureus | Escherichia coli Infections - drug therapy | Bacteremia - drug therapy | Pseudomonas Infections - microbiology | Wound Infection - epidemiology | Catheter-Related Infections - drug therapy | Drug Resistance, Microbial | Escherichia coli Infections - epidemiology | Acinetobacter baumannii | Catheter-Related Infections - microbiology | Adolescent | Bacteremia - epidemiology | Infant | Bacteremia - microbiology | Cephalosporins - therapeutic use | Anti-Bacterial Agents - therapeutic use | Klebsiella Infections - epidemiology | Adult | Female | Pseudomonas aeruginosa | Staphylococcal Infections - microbiology | Wound Infection - drug therapy | Acinetobacter Infections - microbiology | Staphylococcal Infections - drug therapy | Colombia - epidemiology | Klebsiella Infections - drug therapy | Central Venous Catheters | Pneumonia - epidemiology | Pseudomonas Infections - drug therapy | Acinetobacter Infections - drug therapy | Escherichia coli Infections - microbiology | Folliculitis - microbiology | Pneumonia - microbiology | Klebsiella Infections - microbiology | Oxacillin - therapeutic use | Burns - epidemiology | Urinary Tract Infections - drug therapy | Urinary Tract Infections - epidemiology | Pneumonia - drug therapy | Staphylococcal Infections - epidemiology | Pseudomonas Infections - epidemiology | Acinetobacter Infections - epidemiology | Wound Infection - microbiology | Aged | Folliculitis - drug therapy | Klebsiella pneumoniae | Development and progression | Burns and scalds | Surgery, Plastic | Health aspects | Staphylococcus aureus infections | Analysis | Bacterial pneumonia | Mortality | Urinary tract infections | Bacteria | Disease susceptibility | Antibacterial agents
Journal Article
Journal of Infection, ISSN 0163-4453, 2014, Volume 69, Issue 3, pp. 216 - 225
Summary Background An intervention for Gram-negative bloodstream infections that integrated mass spectrometry technology for rapid diagnosis with antimicrobial stewardship oversight significantly... 
Infectious Disease | Bloodstream infections | Multidrug resistant | Antimicrobial stewardship | MALDI-TOF | Rapid diagnostics | MORTALITY | ACQUIRED INFECTIONS | INFECTIOUS DISEASES | METAANALYSIS | IDENTIFICATION | DISEASES SOCIETY | IMPACT | THERAPY | HEALTH-CARE | BLOOD-STREAM INFECTIONS | ENTEROBACTERIACEAE | Humans | Middle Aged | Bacteremia - mortality | Male | Pseudomonas Infections - mortality | Gram-Negative Bacterial Infections - microbiology | Time Factors | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | Escherichia coli Infections - drug therapy | Escherichia coli - enzymology | Time-to-Treatment | Bacteremia - drug therapy | Klebsiella - enzymology | Gram-Negative Bacterial Infections - drug therapy | Pseudomonas Infections - diagnosis | Survival Rate | Pseudomonas Infections - microbiology | Klebsiella Infections - diagnosis | Gram-Negative Bacterial Infections - diagnosis | Hospital Costs | Escherichia coli Infections - mortality | Pseudomonas aeruginosa - isolation & purification | beta-Lactam Resistance | Acinetobacter Infections - mortality | Klebsiella - isolation & purification | Bacteremia - microbiology | Microbial Sensitivity Tests | Anti-Bacterial Agents - therapeutic use | Drug Resistance, Multiple, Bacterial | Acinetobacter baumannii - isolation & purification | Adult | Female | beta-Lactamases - metabolism | Acinetobacter Infections - microbiology | Length of Stay | Escherichia coli Infections - diagnosis | Intensive Care Units | Klebsiella Infections - drug therapy | Acinetobacter Infections - diagnosis | Hospital Mortality | Pseudomonas Infections - drug therapy | Acinetobacter Infections - drug therapy | Escherichia coli Infections - microbiology | Treatment Outcome | Bacteremia - diagnosis | Klebsiella Infections - microbiology | Escherichia coli - isolation & purification | Klebsiella Infections - mortality | Aged | Gram-Negative Bacterial Infections - mortality | Drug resistance in microorganisms | Care and treatment | Mass spectrometry | Patient outcomes
Journal Article
Expert review of anti-infective therapy, ISSN 1478-7210, 2003
Journal
American journal of respiratory and critical care medicine, ISSN 1535-4970, 2016, Volume 193, Issue 5, pp. 504 - 515
Rationale: Cystic fibrosis (CF) is characterized by early structural lung disease caused by pulmonary infections... 
Healthy controls | Cystic fibrosis | Microbiota | Nasopharynx | Longitudinal | microbiota | SMALL-COLONY VARIANTS | CARRIAGE | HAEMOPHILUS-INFLUENZAE | COMMUNITIES | CHILDREN | STREPTOCOCCUS-PNEUMONIAE | INHIBITION | RESPIRATORY SYSTEM | cystic fibrosis | INFLAMMATION | LUNG-DISEASE | STAPHYLOCOCCUS-AUREUS | longitudinal | nasopharynx | healthy controls | CRITICAL CARE MEDICINE | Carrier State - epidemiology | Streptococcus mitis - genetics | Prospective Studies | Humans | Corynebacterium Infections - epidemiology | Carrier State - microbiology | Haemophilus Infections - epidemiology | Infant | Male | Corynebacterium Infections - microbiology | Case-Control Studies | Anti-Bacterial Agents - therapeutic use | Enterobacteriaceae Infections - epidemiology | Female | Staphylococcal Infections - microbiology | Nasopharynx - microbiology | Real-Time Polymerase Chain Reaction | Burkholderia Infections - microbiology | Haemophilus Infections - drug therapy | Infant, Newborn | Staphylococcus aureus - genetics | Moraxellaceae Infections - epidemiology | Streptococcal Infections - microbiology | Burkholderia - genetics | Staphylococcal Infections - drug therapy | Burkholderia Infections - epidemiology | Cystic Fibrosis - microbiology | Enterobacteriaceae Infections - microbiology | Enterobacteriaceae - genetics | Moraxellaceae Infections - microbiology | Streptococcal Infections - epidemiology | Haemophilus influenzae - genetics | Corynebacterium - genetics | Cystic Fibrosis - epidemiology | Moraxellaceae Infections - drug therapy | DNA, Bacterial - genetics | Staphylococcal Infections - epidemiology | Corynebacterium Infections - drug therapy | Microbiota - genetics | Burkholderia Infections - drug therapy | Haemophilus Infections - microbiology | RNA, Ribosomal, 16S - genetics | Streptococcal Infections - drug therapy | Moraxella - genetics | Cohort Studies | Enterobacteriaceae Infections - drug therapy
Journal Article
The Journal of infectious diseases, ISSN 1537-6613, 2014, Volume 210, Issue 9, pp. 1357 - 1366
Background. Limitations in treatment of biofilm-associated bacterial infections are often due to subpopulation of persistent bacteria (persisters... 
Biofilms | Antibiotics | Escherichia coli | Bacteria | Aminoglycosides | Pseudomonas aeruginosa | Infections | Basic amino acids | Staphylococcus aureus | aminoglycoside | persister | catheter-related infections | biofilm | proton motive force | DIAGNOSIS | INFECTIOUS DISEASES | INFECTIONS | MANAGEMENT | TOLERANCE | SUSCEPTIBILITY | MICROBIOLOGY | IMMUNOLOGY | ANTIBIOTIC-LOCK THERAPY | GENTAMICIN | PSEUDOMONAS-AERUGINOSA | L-ARGININE | GROWTH | Escherichia coli Infections - prevention & control | Central Venous Catheters - microbiology | Escherichia coli - drug effects | Gentamicins - administration & dosage | Catheter-Related Infections - prevention & control | Pseudomonas Infections - prevention & control | Arginine - administration & dosage | Gentamicins - pharmacology | Drug Therapy, Combination | Biofilms - drug effects | Escherichia coli Infections - drug therapy | Staphylococcal Infections - drug therapy | Pseudomonas Infections - drug therapy | Rats | Central Venous Catheters - adverse effects | Pseudomonas aeruginosa - drug effects | Catheter-Related Infections - drug therapy | Drug Synergism | Animals | Arginine - pharmacology | Staphylococcal Infections - prevention & control | Anti-Bacterial Agents - pharmacology | In Vitro Techniques | Staphylococcus aureus - drug effects | Hydrogen-Ion Concentration | Health aspects | Research | Index Medicus | Abridged Index Medicus | Biofilms/drug effects | Gentamicins/administration & dosage | Anti-Bacterial Agents/pharmacology | Staphylococcal Infections/drug therapy | Arginine/administration & dosage | Life Sciences | Escherichia coli Infections/drug therapy | Staphylococcus aureus/drug effects | Gentamicins/pharmacology | Catheter-Related Infections/prevention & control | Pseudomonas aeruginosa/drug effects | Staphylococcal Infections/prevention & control | Catheter-Related Infections/drug therapy | Central Venous Catheters/microbiology | Escherichia coli/drug effects | Bacteriology | Microbiology and Parasitology | Central Venous Catheters/adverse effects | Arginine/pharmacology | Pseudomonas Infections/prevention & control | Escherichia coli Infections/prevention & control | Pseudomonas Infections/drug therapy
Journal Article
The Lancet infectious diseases, ISSN 1473-3099, 2016, Volume 16, Issue 6, pp. 661 - 673
Journal Article
Clinics in Perinatology, ISSN 0095-5108, 03/2015, Volume 42, Issue 1, pp. 77 - 103
Journal Article
Journal of Preventive Medicine and Hygiene, ISSN 1121-2233, 2017, Volume 58, Issue 4, pp. E294 - E301
National efforts to curtail healthcare-associated infections (HAI) proliferated recently, though data detailing progress over time are limited... 
Bloodstream infections | Urinary tract infections | Antimicrobial resistance | Multidrug-resistant organisms | Surgical site infections | Humans | Middle Aged | Drug Resistance, Bacterial | Male | Incidence | Gram-Negative Bacterial Infections - microbiology | Young Adult | Gram-Positive Bacterial Infections - microbiology | Urinary Tract Infections - microbiology | Odds Ratio | Staphylococcus aureus | Enterococcus | Bacteremia - drug therapy | Gram-Negative Bacterial Infections - drug therapy | Logistic Models | Pseudomonas Infections - microbiology | Gram-Positive Bacterial Infections - epidemiology | Streptococcus pneumoniae | Acinetobacter baumannii | Cross Infection - microbiology | Adolescent | Gram-Negative Bacterial Infections - epidemiology | Bacteremia - epidemiology | New York City - epidemiology | Surgical Wound Infection - microbiology | Gram-Positive Bacterial Infections - drug therapy | Bacteremia - microbiology | Anti-Bacterial Agents - therapeutic use | Klebsiella Infections - epidemiology | Surgical Wound Infection - drug therapy | Adult | Female | Pseudomonas aeruginosa | Retrospective Studies | Staphylococcal Infections - microbiology | Acinetobacter Infections - microbiology | Cross Infection - epidemiology | Streptococcal Infections - microbiology | Staphylococcal Infections - drug therapy | Surgical Wound Infection - epidemiology | Klebsiella Infections - drug therapy | Pneumonia - epidemiology | Pseudomonas Infections - drug therapy | Acinetobacter Infections - drug therapy | Streptococcal Infections - epidemiology | Pneumonia - microbiology | Klebsiella Infections - microbiology | Urinary Tract Infections - drug therapy | Urinary Tract Infections - epidemiology | Pneumonia - drug therapy | Staphylococcal Infections - epidemiology | Pseudomonas Infections - epidemiology | Acinetobacter Infections - epidemiology | Streptococcal Infections - drug therapy | Aged | Klebsiella pneumoniae
Journal Article
The Lancet infectious diseases, ISSN 1473-3099, 2014, Volume 14, Issue 11, pp. 1136 - 1149
.... New viral respiratory tract infections with epidemic potential, such as severe acute respiratory syndrome, swine-origin influenza A H1N1, and Middle East respiratory syndrome coronavirus infection... 
Infectious Disease | INFECTIOUS DISEASES | INFLUENZA-A | ASPERGILLUS-FUMIGATUS | IN-VITRO | VIRUS-INFECTION | A DOUBLE-BLIND | OPEN-LABEL | CRITICALLY-ILL PATIENTS | T-CELLS | SYNDROME CORONAVIRUS | H1N1 VIRUS | Mycoses - epidemiology | Virus Diseases - epidemiology | Biological Therapy - methods | Biological Therapy - trends | Humans | Drug Resistance, Viral | Drug Resistance, Bacterial | Mycoses - microbiology | Virus Diseases - virology | Antifungal Agents - therapeutic use | Respiratory Tract Infections - microbiology | Anti-Bacterial Agents - therapeutic use | Virus Diseases - drug therapy | Respiratory Tract Infections - virology | Drug Resistance, Fungal | Bacterial Infections - microbiology | Drug Therapy - trends | Antifungal Agents - pharmacology | Antiviral Agents - pharmacology | Antiviral Agents - therapeutic use | Bacterial Infections - drug therapy | Drug Discovery - trends | Respiratory Tract Infections - drug therapy | Treatment Outcome | Drug Therapy - methods | Bacterial Infections - epidemiology | Mycoses - drug therapy | Anti-Bacterial Agents - pharmacology | Respiratory Tract Infections - epidemiology | Antiviral agents | Hospitals | Influenza | Mycoses | Development and progression | Bacteria | Cross infection | Nosocomial infections | Drug therapy | Cells | Drug resistance in microorganisms | Severe acute respiratory syndrome | Respiratory agents | Pandemics | Mortality | Respiratory diseases | Viral infections
Journal Article
PloS one, ISSN 1932-6203, 2012, Volume 7, Issue 4, p. e35072
H. pylori drug-resistant strains and non-compliance to therapy are the major causes of H... 
POLYUNSATURATED FATTY-ACIDS | INFECTION | MONOGLYCERIDES | MULTIDISCIPLINARY SCIENCES | Gastritis - drug therapy | Gastric Mucosa - microbiology | Mice, Inbred C57BL | Helicobacter pylori - ultrastructure | Gastric Mucosa - pathology | Helicobacter pylori - drug effects | Male | Docosahexaenoic Acids - administration & dosage | Helicobacter Infections - pathology | Docosahexaenoic Acids - pharmacology | Animals | Gastritis - pathology | Helicobacter Infections - drug therapy | Gastritis - microbiology | Anti-Bacterial Agents - pharmacology | Mice | Anti-Bacterial Agents - administration & dosage | Helicobacter Infections - microbiology | Unsaturated fatty acids | Helicobacter pylori | Growth | Analysis | Helicobacter infections | Health aspects | Omega-3 fatty acids | Antiulcer drugs | Therapy | Stomach | Disease | Fish oils | Gastric mucosa | Infections | Drug resistance | Docosahexaenoic acid | Fatty acids | Stomach cancer | Inflammatory diseases | Medicine | Studies | Pathology | Immunology | Antibiotics | Ulcers | Biomarkers | Bacteria | In vivo methods and tests | Colonization | Helicobacter Infections/drug therapy | Docosahexaenoic Acids/administration & dosage | Anti-Bacterial Agents/administration & dosage | Helicobacter Infections/pathology | Helicobacter Infections/microbiology | Gastritis/drug therapy | Anti-Bacterial Agents/pharmacology | Bacteriology | Helicobacter pylori/drug effects | Helicobacter pylori/ultrastructure | Gastritis/pathology | Life Sciences | Microbiology and Parasitology | Human health and pathology | Gastritis/microbiology | Infectious diseases | Gastric Mucosa/microbiology | Gastric Mucosa/pathology
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2010, Volume 376, Issue 9738, pp. 367 - 387
...-HIV-associated comorbidities. Tuberculosis co-infection in HIV-infected drug users, including disease caused by drug-resistant strains, is acquired and transmitted as a consequence of inadequate prescription of antiretroviral... 
Internal Medicine | SOFT-TISSUE INFECTIONS | MEDICINE, GENERAL & INTERNAL | OPIOID SUBSTITUTION TREATMENT | HEPATITIS-C VIRUS | SMOKING-CESSATION PHARMACOTHERAPIES | CLINICAL-TRIAL | TREATMENT OUTCOMES | METHADONE-MAINTENANCE | ADMINISTERED ANTIRETROVIRAL THERAPY | RANDOMIZED CONTROLLED-TRIAL | HUMAN-IMMUNODEFICIENCY-VIRUS | HIV Infections - epidemiology | Humans | Drug Resistance, Bacterial | Narcotics - therapeutic use | Criminal Law | Anti-HIV Agents - administration & dosage | Hepatitis, Viral, Human - epidemiology | Drug Interactions | Antipsychotic Agents - therapeutic use | Substance-Related Disorders - epidemiology | Tuberculosis - drug therapy | Anti-HIV Agents - therapeutic use | HIV Infections - mortality | Substance-Related Disorders - mortality | Antitubercular Agents - therapeutic use | Mental Disorders - epidemiology | Antiviral Agents - therapeutic use | Bacterial Infections - drug therapy | Comorbidity | AIDS-Related Opportunistic Infections - drug therapy | Evidence-Based Medicine | Narcotics - administration & dosage | Medication Adherence | Mental Disorders - drug therapy | AIDS-Related Opportunistic Infections - epidemiology | Bacterial Infections - epidemiology | HIV Infections - drug therapy | Substance-Related Disorders - drug therapy | Hepatitis, Viral, Human - drug therapy | Prisoners | Prevention | Complications and side effects | Drug addicts | Research | Drug therapy | Health aspects | HIV infection | Mental illness | Risk factors | Cardiovascular diseases
Journal Article